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ABSTRACT: Brain diseases are a major health 
challenge as brain drug delivery is truly hindered by the 
blood-brain barrier. Therefore, targeted drug 
nanocarriers arise as an alternative to achieve efficient 
transport across the brain endothelium following 
minimally-invasive intravenous injection. However, the 
global translational impact of nanomedicine remains 
modest. Certainly, the transition from empirical 
development towards a rational design tailored to the 
specific disease needs is likely to improve the chances 
of success. 
Under this assumption and taking advantage of both the 
natural brain tropism and the antiproliferative activity of 
cannabidiol, to contribute to the rational design of 
targeted nanocapsules for glioma therapy, we have 
thoroughly screened the influence of distinct parameters 
on their in vitro and in vivo behaviour. Effectively, we 
have demonstrated that both the brain and glioma 
targeting ability and the drug release rate can be tailored 
by varying the particle size of the nanocapsules. This 
fine size-tailoring can be achieved by the phase 
inversion temperature method thanks to the herein-
described linear univariate mathematical model as a 
function of the oily phase/surfactant mass ratio. 
Moreover, we have introduced, on the one hand, a 
pioneering brain tumor targeting strategy with 
cannabidiol (with better targeting properties than other 
strategies that have already reached the clinical trials 
stage) and, on the other hand, nanocapsules as extended-
release carriers of cannabidiol to overcome the 
formulation problems that have traditionally constrained 
its therapeutic potential. 
Altogether, small lipid nanocapsules loaded and 
functionalized with cannabidiol arise as promising 
dually-targeted candidates for intravenous treatment of 
glioma. 
 
RESUMEN: Las patologías cerebrales representan un 
desafío terapéutico por la restricción al paso de 
fármacos a través de la barrera hematoencefálica. Por 
ello, actualmente se persigue diseñar transportadores de 
fármacos capaces de atravesar de manera eficiente el 
endotelio cerebral tras su administración intravenosa. 
Sin embargo, el impacto traslacional de la nanomedicina 
es aún discreto. Sin duda, la transición de un desarrollo 
empírico hacia un diseño racional adecuado a las 
necesidades terapéuticas concretas en cada caso 
aumentará las posibilidades de éxito. 
Bajo esta premisa y aprovechando tanto el tropismo 
cerebral como la actividad antiproliferativa del 
cannabidiol, y a fin de contribuir al diseño racional de 
nanocápsulas dirigidas para el tratamiento de gliomas, 
hemos evaluado la influencia de distintos parámetros en 
su comportamiento in vitro e in vivo. Efectivamente, 
hemos demostrado que tanto el paso a través de barrera 
hematoencefálica como la captación por células de 
glioma, así como la velocidad de liberación de fármacos 
pueden modularse variando su tamaño de partícula. El 
método térmico de inversión de fases posibilita la 
obtención de nanocápsulas bajo demanda en términos de 
tamaño gracias al modelo matemático lineal en una 
variable aquí descrito. 
Además, hemos desarrollado una novedosa estrategia de 
vectorización con cannabidiol (que incluso supera a 
otras que ya se encuentran en ensayos clínicos). 
Asimismo, las nanocápsulas sirven como 
transportadores de liberación prolongada del 
cannabidiol, superando así sus problemas de 
formulación que venían limitando su potencial 
terapéutico. 
En conjunto, las nanocápsulas lipídicas, cargadas y 
funcionalizadas con cannabidiol, constituyen 
prometedores candidatos para el tratamiento de gliomas. 
 
ANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA 
ISSN (Online) 1697-4298 
Article 
analesranf.com 
Nannocannabinoids for brain tumor drug delivery 
@Real Academia Nacional de Farmacia. Spain 199 
1. INTRODUCTION 
Brain diseases should be considered a major health 
challenge as brain drug delivery is truly hindered by the 
blood-brain barrier (BBB) (1). The BBB consists of the 
endothelium of brain capillaries. The key features of the 
brain endothelium that severely restrict brain drug delivery 
are both the lack of fenestrations and the presence of tight 
intercellular junctions. Hence, there is a dire need for 
developing effective brain drug delivery strategies that 
overcome the biodistribution limitations that account for 
treatment failure (2). 
Some of the described delivery strategies to circumvent 
the BBB such as the intracerebral administration and the 
artificial disruption of the tight junctions involve high risk 
of neurological damage and even of widespread tumor 
dissemination in the case of brain tumors. Therefore, the 
use of targeted drug nanocarriers arises as a promising 
alternative to achieve efficient transport across the brain 
endothelium following minimally-invasive intravenous 
injection (3-5). 
Unfortunately, the global translational impact of 
nanomedicine remains modest. In this context, we have 
analyzed the possibilities and technological challenges 
ahead to improve the chances of success in the 
development of nanomedicines for brain pathologies. 
Certainly, whereas the empirical development of delivery 
systems and their subsequent application to a specific 
disease has led to high attrition rates in clinical trials, the 
transition towards a disease-driven approach, whereby the 
nanomedicine features are rationally defined beforehand 
based on the pathophysiology of a specific disease is more 
likely to succeed. 
One of the major features that influence the in vivo 
behaviour of nanocarriers is particle size as their effect 
mainly relies on the unique interactions of materials at the 
nanoscale with biological structures. For instance, a size-
driven extravasation at tumor and/or inflammatory sites 
based on their pathophysiological features (namely, the 
enhanced permeation and retention (EPR) effect) has been 
sought. However, the EPR effect in brain diseases is 
relatively weak due to the presence of the BBB, with a cut-
off size of only 10-100 nm (6). In these cases, a much finer 
control over particle size will certainly improve the 
potential therapeutic benefits. Hence, rational disease-
driven design of nanocarriers can only be achieved by 
determining the parameters that accurately control their 
size distribution. 
Under this assumption, we have thoroughly studied 
which parameters control the size distribution of lipid 
nanocapsules (LNCs) prepared by the phase inversion 
temperature (PIT) method. The PIT method is a low-
energy nanoemulsification method wherein the 
physicochemical properties of surfactants are exploited to 
lower the required energy input for nanoemulsification 
according to the Young-Laplace equation for a spherical 
drop. To this end, the PIT method profits from the 
negligible interfacial tension achieved when the surfactant 
curvature is inverted by changes in temperature. At the 
“phase inversion temperature”, the affinity for both phases 
is balanced and the minimum in interfacial tension is 
achieved (7). As the final formulation is obtained 
following a thermal quench below the surfactant melting 
point, nanoemulsions eventually adopt the form of 
nanocapsules with a liquid oily core stabilized by a rigid 
surfactant shell. 
With around a quarter of a million new cases of brain 
tumors every year, these brain diseases could take great 
advantage of LNCs. Brain tumors are stratified according 
to a ‘malignancy scale’ (8). Malignant primary brain 
tumors typically originate from glial cells (being thus 
referred to as gliomas). The current standard approach in 
high grade gliomas combines maximal surgical resection 
(if eligible) with radiotherapy and chemotherapy; as well 
as symptomatic treatment. Unfortunately, the efficacy of 
this treatment remains questionable, since recurrence 
happens within months after diagnosis, with a median 
survival of 14.6 months (9). 
In the search for novel antitumor agents, the 
therapeutic potential of several cannabinoids has become a 
research hotspot as they have been reported to not only 
palliate cancer-related symptoms (such as nausea, pain or 
anorexia) but also promote apoptotic cancer cell death, 
impair tumor angiogenesis and reduce cell migration (10, 
11). Cannabinoids are pharmacologically-active 
terpenophenols that can be ascribed to three distinct 
categories: phytocannabinoids (produced by the glandular 
trichomes of the herbaceous plant Cannabis sativa (12)), 
endocannabinoids (produced naturally by animals and 
humans) and synthetic cannabidomimetics (13). However, 
the therapeutic potential of cannabinoids has been truly 
constrained heretofore due to their strong psychoactive 
effects and their high lipophilicity. 
Precisely due to the lack of these psychoactive effects, 
cannabidiol (CBD) arises as the phytocannabinoid with the 
greatest potential to widen the therapeutic armamentarium 
for the treatment of gliomas thanks to its synergism with 
the currently available chemo and radiotherapy (14). As a 
proof of it, CBD has reached the clinical trials stage as 
adjuvant therapy for patients with glioblastoma 
(ClinicalTrials.gov identifiers: NCT01812616, 
NCT01812603, NCT03246113 and NCT03529448). 
Moreover, cannabinoids can take great advantage of 
nanomedicine-based formulation strategies to overcome 
the dosing problems traditionally associated with their 
high lipophilicity. Accordingly, several studies on 
nanocarriers encapsulating different kinds of cannabinoids 
have been published for distinct therapeutic purposes 
(Table 1). Notwithstanding that for cannabinoids to 
achieve high translational impact they should be devoid of 
psychoactive effects; the focus so far has been mainly put 
on 9-delta-tetrahydrocannabinol (Δ9-THC) and its 
analogues. Hence, we have evaluated herein LNCs as 
biocompatible carriers for CBD. 
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Table 1:  Published articles on the encapsulation of different kinds of cannabinoids within nanocarriers.  9Δ-THC: 
9-delta-tetrahydrocannabinol,  AEA: anandamide.  
Cannabinoid Type of cannabinoid Carrier Therapeutic potential  Ref 
9Δ-THC Phytocannabinoid Mesoporous silica nanoparticles In vivo neuropathic pain relief (15) 
9Δ-THC Phytocannabinoid PLGA nanoparticles In vitro and in vivo chemotherapy for lung cancer (16) 
9Δ-THC Phytocannabinoid PLGA nanoparticles In vitro chemotherapy for colon adenocarcinoma (17) 
9Δ-THC and CBD Phytocannabinoid Nanolipospheres - (18) 
AEA Endocannabinoid Poly-ε-caprolactone nanoparticles - (19) 
Rimonabant Synthetic cannabidomimetic Nanostructured lipid carriers - (20) 
Rimonabant, URB597 
and AM251 Synthetic cannabidomimetic 
Nanostructured lipid 
carriers - (21) 
WIN55,212-2 Synthetic cannabidomimetic Styrene maleic acid micelles In vivo neuropathic pain relief (22) 
Dexanabinol Synthetic cannabidomimetic Solid lipid nanoparticles In vivo antidepressant effect (23) 
CB13 Synthetic cannabidomimetic PLGA nanoparticles In vivo neuropathic pain relief (24) 
CB13 Synthetic cannabidomimetic PLGA nanoparticles - (25, 26) 
CB13 Synthetic cannabidomimetic Lipid nanoparticles - (25, 27) 
To be efficacious following intravenous administration, 
these carriers must be able to traverse the BBB to 
ultimately reach the tumor cells. Unfortunately, although 
the paracellular permeability of the brain endothelium is 
altered in most brain diseases, this disruption only occurs 
substantially in advanced stages of disease and in the most 
affected regions (28, 29). Therefore, brain targeting should 
not solely rely on passive targeting. Alternatively, brain 
active targeting is being explored to boost the transcellular 
delivery efficiency of nanocarriers across the BBB (30). 
Brain active targeting is based on the modification of 
nanocarriers with moieties that trigger receptor-mediated 
transcytosis into the central nervous system (CNS) through 
specific binding with transporters overexpressed on the 
brain endothelium. Although numerous receptors have 
been used to design brain active targeting strategies across 
the BBB, the translational impact of brain active targeting 
remains modest, as only three actively-targeted liposomes 
have reached the clinical trials stage for distinct brain 
conditions (ClinicalTrials.gov identifiers: NCT01386580, 
NCT02048358 and NCT02340156) due to the flaws of the 
currently available targeting moieties (namely, the 
development of competitive phenomena with endogenous 
ligands and/or of immunogenicity) (31, 32). 
Therefore, research on novel exogenous non-
immunogenic moieties is likely to thrive shortly. In this 
respect, CBD has been reported to bind to various 
receptors located on the brain endothelium environment: 
namely, cannabinoid receptors CB1 (33) and CB2 (34), 
serotoninergic receptor 5-HT1A (35), transient potential 
vanilloid receptors TRPV1–2 (36), glycine receptor (37), 
adenosine receptor A2A (38), G-protein-coupled receptor 
55 GPR55 (39) and dopamine receptor D2 (40)). 
Apart from those receptors normally overexpressed on 
the brain endothelium, those overexpressed on tumor cells 
can also be used for active targeting of brain tumors to 
promote the selective distribution to glioma cells. In this 
respect, the expression of some of the receptors to which 
the cannabinoids bind has been reported to be increased in 
glioma (namely, cannabinoid receptors 1 and 2 (CB1 and 
CB2) (41), transient potential vanilloid receptor type 2 
(TRPV2) (36) and G-protein-coupled receptor 55 (GPR55) 
(42). 
Hence, we have designed two distinct strategies to 
incorporate CBD in the aforesaid size-tailored LNCs for 
glioma therapy depending on the ultimate therapeutic 
purpose. On the one hand, we have introduced herein a 
pioneering functionalization strategy for brain tumor 
targeting of LNCs with CBD under the assumption that, if 
existing, this double BBB- and glioma-targeting effect will 
ultimately enable a dual-targeting strategy for intravenous 
treatment of glioma to be achieved. The BBB-targeting 
efficiency of this active targeting strategy has been 
explored in vitro and in vivo, whereas the glioma-targeting 
efficiency has been assessed in vitro with the human 
glioblastoma cell line U373MG. As the mechanisms that 
drive the distinct active targeting strategies may follow a 
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size-dependent pattern, the role played by the particle size 
of LNCs in the extent of targeting has concomitantly been 
evaluated. On the other hand, we have encapsulated CBD 
into the oily core of LNCs and assessed in vitro their 
efficacy as extended-release carriers of CBD against the 
U373MG cell line. The role played by the size of LNCs in 
drug release and cytotoxicity has also been evaluated.. 
2.  MATERIALS AND METHODS 
2.1. Materials 
Labrafac® lipophile WL 1349 (caprylic-capric acid 
triglycerides) and Labrafil® M 1944 CS (6-macrogol oleic 
glycerides) were kindly supplied by Gattefossé. Kolliphor® 
HS15 (C18E15 polyethylene glycol (15) 12-
hydroxystearate) and Kolliphor® ELP (C18Δ9E35 
polyethylene glycol (35) ricinoleate) were gifts from 
BASF. Lipoid® S75 (soybean lecithin with 70% of 
phosphatidylcholine) was supplied by Lipoid-Gmbh. NaCl 
was purchased from Panreac. De-ionized water was 
obtained from a MilliQ® Purification System. The 
ﬂuorescent dyes 3,3'-dioctadecyloxacarbocyanine 
perchlorate (DiO) and 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine 4-chlorobenzenesulfonate 
salt (DiD) were purchased from Invitrogen Molecular 
Probes. Cannabidiol (CBD) was provided by THC-
Pharma. Endothelial Cell Basal Medium-2 (EBM-2) and 
its culture supplements were purchased from Lonza. 
Dulbecco’s Modified Eagle Medium (DMEM) and 
penicillin-streptomycin (10,000 U/mL) were provided by 
Gibco. Tetramethyl-rhodamine-isothiocyanate–dextran 
(TRITC-dextran, MW 150 kDa), type I collagen from calf 
skin, fibronectin from bovine plasma, Hank’s Balanced 
Salt Solution (HBSS), 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT), dimethyl-
sulfoxide (DMSO) and sterile Nunc Lab-Tek® chamber 
slides (8 wells, Permanox® slide, 0.8 cm2/well) were 
purchased from Sigma-Aldrich. Vectashield® mounting 
medium with DAPI (H-1200) was provided by Vector 
Laboratories. Sterile Millicell® Hanging Cell Culture 
Inserts (12-well culture plates; membrane: polyethylene 
terephthalate membrane; pore size: 1.0 µm; membrane 
surface area: 1.1 cm2) and Amicon® Ultra 15 mL 
Centrifugal Filters (MWCO: 10 kDa) were supplied by 
Merck Millipore. Methanol, acetonitrile and 
tetrahydrofuran HPLC grade were purchased from Fisher 
Scientific. 
2.2. Cell lines 
The human brain endothelial hCMEC/D3 cells were 
seeded in collagen-coated flasks and cultured in EBM-2 
medium supplemented with 2.5% foetal bovine serum 
(FBS), 0.025% (v/v) rhEGF, 0.025% (v/v) VEGF 0.025% 
IGF, 0.1% (v/v) rhFGF, 0.1% (v/v) gentamycin, 0.1% 
(v/v) ascorbic acid and 0.04% (v/v) hydrocortisone at 
37ºC  and 5% CO2. For all experiments, cells between 
passage 25 and 30 were used. 
The human glioblastoma U373MG cells were cultured 
in DMEM medium supplemented with 10% FBS, 100 
U/mL penicillin and 100 µg/mL streptomycin at 37ºC and 
5% CO2. For all experiments, cells between passage 15 
and 25 were used. 
2.3. Animals 
Male ICR mice (4-5 weeks old) were purchased from 
Envigo. The mice were housed in ventilated cages with 
free water and food in a 12h dark/light cycle. All in vivo 
experiments were approved by the Ethics Committee of 
the Community of Madrid (Ref. PROEX 111/14) and 
conducted according to Spanish and European guidelines 
(Directive 86/609/EEC). 
2.4. Preparation and characterization of LNCs 
LNCs were prepared by the PIT method (43). Briefly, 
all excipients (namely, aqueous and oily phases along with 
nonionic polyethoxylated surfactants) were mixed under 
magnetic stirring and progressively heated over the phase 
inversion temperature of the system. Subsequently, the 
mixture was gradually cooled down until the phase 
inversion temperature was reached. Then, a sudden quench 
with cold water (5 mL) was performed to obtain the final 
suspension of LNCs. Different formulations of LNCs were 
prepared by varying the relative proportions of their 
excipients and the surfactant/oil affinity, i.e. changing the 
nature of the surfactant (between Kolliphor® HS15 and 
Kolliphor® ELP) and of the oil (between Labrafac® 
lipophile WL1349 and Labrafil® M 1944 CS). 
2.4.1. Size distribution and zeta potential 
The average volume diameter and polydispersity index 
(PdI) were measured by dynamic light scattering (DLS) 
with a Microtrac® Zetatrac™ Analyzer (Microtrac Inc.). 
The zeta potential was measured using a Zetasizer Nano 
ZS (Malvern Instruments). 
2.4.2. Incorporation efficiency and drug content 
The CBD content in the CBD-decorated and CBD-
loaded LNCs was determined by high performance liquid 
chromatography (HPLC). A mixture of methanol: 
acetonitrile: water (52:30:18 v/v) at a flow rate of 1.8 
mL/min was used as mobile phase. The analytical column 
was a reversed-phase Mediterranea Sea® C18 (5µm 15 x 
0,46 cm) (Teknokroma®). The amount of CBD associated 
with LNCs in each case was determined as the difference 
between the total amount of CBD in suspension derived 
from the lysis of LNCs with tetrahydrofuran (1:5 (v/v)) 
and the unassociated CBD filtered with 10 kDa Amicon® 
Centrifugal Filters (6000 rpm, 60 min). 
2.5. In vitro evaluation of the BBB and glioma targeting 
ability of the CBD functionalization strategy 
2.5.1. CBD decoration of LNCs 
The fluorescent dye DiO was encapsulated in LNCs for 
in vitro experiments. To this end, the fluorescent dye was 
dissolved in the oily core of the LNCs at a weight ratio of 
15 mg of dye/g of Labrafac® WL1349. Pre-formed 
fluorescently-labeled LNCs were incubated with a CBD 
solution (15 mg/mL) in a 3:1 (v/v) ratio. The mixture was 
gently stirred overnight until complete solvent 
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evaporation. 
2.5.2. Uptake experiments 
Flow cytometry was used to quantitatively evaluate the 
BBB and glioma targeting ability in vitro. hCMEC/D3 and 
U373MG cells were separately seeded into 6-well plates. 
After cells had been confluent for 48 hours, the culture 
medium was replaced by fluorescently-labeled LNCs at an 
equivalent dye concentration of 1.65 µg DiO/mL of 
medium. After 24 hours incubation, cells were rinsed, 
trypsinized and finally resuspended in 0.3 mL of HBSS. 
The fluorescence intensity of cells treated with 
fluorescent-LNCs was analyzed with a flow cytometer 
(FACScalibur, BD Biosciences). Cells treated with blank 
LNCs served as control. 
Confocal microscopy was used to qualitatively 
illustrate the BBB and glioma targeting ability in vitro. 
hCMEC/D3 and U373MG cells were separately seeded 
into chamber slides. After cells had been confluent for 48 
hours, the culture medium was replaced by fluorescently-
labeled LNCs at an equivalent dye concentration of 1.65 
µg DiO/mL of medium. After 24 hours incubation, cells 
were rinsed and mounted with Vectashield® with DAPI 
mounting medium. The cells were then observed with a 
Leica SP5 microscope (405 nm for DAPI, 488 nm for 
DiO). Cells treated with blank LNCs served as control. 3D 
imaging reconstruction was made with IMARIS software. 
2.5.3. BBB permeability experiments 
hCMEC/D3 cells were seeded into collagen- and 
fibronectin-coated hanging cell culture inserts at 
confluence and incubated for 72 hours in complete EBM-
2. The monolayer integrity was assessed by determining 
the permeability coefficient across the hCMEC/D3 
monolayer of TRITC-dextran both in the presence and the 
absence of LNCs. Briefly, a TRITC-dextran solution (2 
mg/mL) was added in the apical chamber and at 2, 4, 6, 8, 
12 and 24 hours, 200 µL from the basolateral compartment 
were sampled and replaced with fresh medium. At 24 
hours, the apical compartment was likewise sampled (100 
µL). Similarly, in a separate experiment, fluorescently-
labeled LNCs at an equivalent dye concentration of 1.65 
µg DiO/mL were added in the apical chamber to determine 
the permeability coefficient of the different formulations 
across the hCMEC/D3 monolayer. The concentration of 
TRITC-dextran and DiO were determined using a 
microplate reader (FLUOstar Omega, BMG Labtech; λexc 
dextran: 544 nm, λem dextran: 590 nm, λexc DiO: 485 nm, 
λem DiO: 520 nm). These concentrations were used to 
calculate the permeability coefficients using the equations 
from (44). 
2.6. In vivo evaluation of the BBB targeting ability of 
CBD-decorated LNCs 
For biodistribution studies in healthy mice, DiO was 
replaced by the fluorescent dye DiD. Mice (n=4-5 per 
group) were injected via the tail vein with 150 µL of DiD-
fluorescently-labeled LNCs. Ninety minutes after 
administration, mice were sacrificed, and the brain, liver, 
spleen, kidneys, lungs, heart and blood were collected and 
homogenized in ethanol for dye extraction. The 
concentration of DiD was measured using a microplate 
reader (Varioskan Flash, Thermo Scientific, excitation 
wavelength: 644 nm, emission wavelength: 665 nm). 
Results were expressed as percentage of the injected dose 
per gram of organ. 
2.7. In vitro efficacy of CBD-loaded LNCs against 
U373MG cells 
2.7.1. CBD loading into the LNCs core 
CBD was encapsulated in the oily core of LNCs for in 
vitro efficacy experiments by dissolving it at a 
concentration of 15 % CBD/ Labrafac® WL1349 (w/w). 
Then, the remaining excipients were added and 
progressively heated and cooled down around the phase 
inversion temperature as indicated above. 
2.7.2. Cytotoxicity experiments 
U373MG cells were seeded into 96-well plates. After 
48 hours of incubation, cells were treated with LNCs (200 
µL) for 48 and 96 hours. Then, the in vitro cytotoxicity of 
CBD-loaded LNCs was determined using an MTT assay. 
For each formulation of CBD-loaded LNCs, U373MG 
cells treated with their blank counterparts served as 
control. Cell viability was expressed as a percentage 
relative to that of control. The half-maximal inhibitory 
concentration (IC50) was calculated in each case. 
2.8. Statistical analysis 
The data are expressed as mean ± SD of at least three 
different experiments. Unpaired Student’s t test was used 
for two-group comparisons. One-way ANOVA followed 
by post-hoc Tukey test were used for multiple-group 
analysis. Statistical significance was fixed as *: p<0.05, 
**: p<0.01, ***: p<0.001. All the data were analyzed 
using the GraphPad Prism 7 software. 
3.  RESULTS AND DISCUSSION 
3.1. Determination of the parameters that control the size 
distribution of LNCs prepared by the PIT method 
The parameters that control the properties of 
nanocarriers can be classified into formulation or 
preparation variables. For low-energy methods (as it is the 
case of the PIT method), the formulation variables, and 
particularly the relative proportion of excipients, are the 
key parameters, as these methods do not rely either on 
physical energy input or on shear forces. Since Morales et 
al (45) showed that water only acts as a dilution medium 
for the dispersed phase, we hypothesized that surfactant 
and oil should be considered the formulation-driving 
parameters. In this respect, particle size is expected to be 
reduced with increasing amounts of surfactant due to the 
decrease in interfacial tension and to grow with increasing 
amounts of oil, as it constitutes the liquid core of the 
nanocapsules. As a result, the oily phase/surfactant mass 
ratio seems to be a suitable variable for prediction of the 
particle size of LNCs prepared by the PIT method. 
Effectively, as shown in Figure 1 and Table 2, we have 
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evidenced herein that the oily phase/surfactant mass ratio 
is the major parameter that drives nanocapsule formation 
for different oil-surfactant combinations (namely, 
Labrafac® WL1349-Kolliphor® HS15, Labrafac® 
WL1349-Kolliphor® ELP, Labrafil® M 1944 CS-
Kolliphor® HS15). These combinations exhibit distinct 
oil/surfactant affinities as summarized in Table 3 in terms 
of HLB. The plot of the average volume diameters versus 
the oil/surfactant ratio was linear within the ratio range 
between 0.08 and 3 and this linear trend is consistent 
through the distinct surfactant-oil affinities. According to 
the high coefficients of determination observed (R2>0.99), 
these univariate linear mathematical models are well-
suited to predict the particle size of the nanocapsules 
prepared by the PIT method. As hypothesized, particle size 
increased along with the oil/surfactant ratio: higher ratios 
represent a decrease in surfactant relative concentration, 
and ultimately lead to bigger capsules. The estimation of 
particle size with a univariate mathematical model is of the 
greatest importance as it will intuitively teach formulators 
how to tailor particle size of LNCs prepared by the PIT 
method to the therapeutic needs imposed by a specific 
disease. Highly monodisperse LNCs were obtained in all 
cases: the polydispersity indexes (PdI) were maintained 
under 0.06, regardless the particle size, well below the 
most broadly used upper limit for monodisperse criteria of 
0.1. 
 
Figure 1: Univariate l inear regression between the average volume diameter and the oil/surfactant mass ratio of 
LNCs prepared by the PIT method.  
Table 2: Parameters of the univariate l inear regression between the average volume diameter and the oil/surfactant 
mass ratio for the different combinations tested.  
Oil/surfactant tandem Y-intercept Slope R2 
Labrafac® lipophile WL1349- Kolliphor® 
HS15 8.83 28.16 0.9983 
Labrafac® lipophile WL1349- Kolliphor® ELP 9.59 22.13 0.9996 
Labrafil® M 1944 CS- Kolliphor® HS15 11.23 11.11 0.9939 
Table 3: HLB values of the different oily phases and polyethoxylated surfac tants as declared by suppliers.  
Excipient HLB value 
Labrafac® lipophile WL1349 1 
Labrafil® M 1944 CS 9 
Kolliphor® ELP 13 
Kolliphor® HS15 15 
Importantly, a comparison among the linear plots for 
the different oil-surfactant tandems can be drawn. On the 
one hand, there are not statistically significant differences 
in the Y-intercept (Table 2), which means that there exists 
a lower limit of particle size to be obtained with the PIT 
method and this limit equals 10 nm. On the other hand, we 
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observe significant differences in the slopes (***: 
p<0.001). As shown in Table 2, the steepest slope was 
achieved for the Labrafac®-Kolliphor® HS15 tandem (b = 
28.16), whereas the lowest value corresponded to the 
Labrafil®-Kolliphor® HS15 (b = 11.11). This difference in 
the slopes can be explained by the difference between the 
HLB values of the poly-ethoxylated surfactants and the 
triglycerides used as oily phase. The slopes follow this 
pattern: the closer the HLB affinity between the surfactant 
and the oily phase, the lower the slope of the linear plot. 
As a result, the size of nanocapsules can be precisely 
tailored to each therapeutic purpose within the range of 10-
100 nm. Importantly, since the univariate linear model has 
been established for surfactants and oily phases with 
different affinities, this tailoring can also be made in terms 
of adjusting the excipients to therapeutic needs. For 
example, solubility issues dictated by a given drug can 
presumably be addressed by changing the oily phase to 
one that fully solubilizes it. Alternatively, toxicological 
concerns related to a given surfactant can be overcome as 
nanocapsules of the same size can be obtained at a lower 
surfactant concentration by switching to an emulsifier with 
a lower HLB or by switching to an oily phase with a 
higher HLB. This can ultimately help increase the 
maximum tolerated dose. These latter cases are illustrated 
in Figure 1. For a given volume diameter, fixed in 30 nm, 
a formulation with a 0.752 ratio for the Labrafac® 
WL1349-Kolliphor® HS15 tandem can be used. However, 
according to our results, there are other alternatives. On 
the one hand, the Kolliphor® HS15 with a HLB of 15 can 
be switched to another poly ethoxylated surfactant with a 
lower HLB (namely, Kolliphor® ELP with a HLB of 13) 
and this change will imply a reduction in the surfactant 
amount, as it will require a higher oil/surfactant ratio 
(0.922). On the other hand, the oily phase can likewise be 
modified to ultimately reduce the amount of surfactant. 
The replacement of Labrafac® WL1349 with a HLB of 1 
by Labrafil® M 1944 CS with a HLB of 9 will enable 30-
nm sized nanocapsules to be obtained at an oil/surfactant 
ratio of 1.689, which halves the required amount of 
surfactant. 
This finding refutes the broadly-agreed requirement for 
a surfactant with an optimum HLB number for a given oily 
phase. The reason may lie in the fact that the HLB number 
concept, defined at 25ºC, only considers the surfactant 
molecule itself and overlooks the interactions with the 
aqueous and oily phases under the influence of external 
parameters. 
Furthermore, the linear univariate mathematical model 
serves to predict the particle size of nanocapsules prepared 
by other authors through not only the PIT method, but also 
through other phase inversion methods (Table 4). This 
unequivocally validates that the oil/surfactant mass ratio is 
the leading parameter that controls size distribution of final 
suspensions. 
Table 4: Parameters of the univariate l inear regression between the average volume diameter and the oil/surfactant 
mass ratio for the different combinations tested.  
Preparation method R2 Ref. 
Phase inversion temperature 0.9928 (46) 
Phase inversion temperature 0.9908 (47) 
Phase inversion temperature 1 (48) 
Phase inversion composition 0.99 (49) 
Phase inversion composition 0.9992 (50) 
Phase inversion composition 0.993 (51) 
Phase inversion composition 0.9789 (52) 
Altogether, these results serve to envisage LNCs 
prepared by the PIT method as promising carriers for the 
treatment of brain diseases following a disease-driven 
design. 
3.2. Determination of BBB and glioma targeting ability of 
fluorescently-labeled LNCs 
Monodisperse LNCs with the Labrafac®-Kolliphor® 
HS15 tandem were prepared in two different sizes and 
loaded with fluorescent dyes for particle tracking purposes. 
Whereas the fluorescent dye DiO was encapsulated for in 
vitro experiments, we used the fluorescent dye DiD in in 
vivo experiments because it is excited and emits within the 
near-infrared window (namely, the wavelength range with 
the lowest absorption in tissue). 
Both kinds of fluorescently-labeled LNCs were 
functionalized with CBD to assess the potential of this 
cannabinoid to enhance the brain tumor targeting 
properties. High CBD adsorption efficiencies were 
achieved with this functionalization strategy (Table S1), 
which doubled those reported by Balzeau et al with a 
targeting peptide following a similar procedure (53). These 
results could be explained by the lower aqueous solubility 
of CBD than that of peptides, which eventually favors its 
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adsorption at the amphiphilic interface. 
Overall, the size distribution features of both types of 
fluorescently-labeled LNCs were analogous. As shown in 
Figure 2, the encapsulation of the fluorescent dyes did not 
alter the size of blank LNCs (20 nm and 40 nm, 
respectively). Conversely, the adsorption of CBD on 
fluorescently-labeled LNCs increased their particle size 
from 20 to 40 nm and from 40 to 55-60 nm. This increase 
followed an inverse size-related pattern: a 100%-increase 
for the smaller LNCs versus a 48%-increase for the bigger 
ones. The higher specific surface area of the smaller LNCs 
can account for this trend observed upon CBD 
functionalization. Moreover, the zeta potential profiles of 
CBD-adsorbed LNCs were noticeably sharpened in 
comparison with those of blank LNCs (Figure S1). These 
profiles support the superficial location of the adsorbed 
CBD. 
 
Figure 2: Average volume diameter of the different LNCs used to assess the BBB and glioma targeting abili ty:  
blank LNCs (orange),  non-functionalized fluorescently-labeled LNCs (DiO: gold; DiD: navy blue) and CBD-
adsorbed fluorescently-labeled LNCs (DiO: turquoise,  DiD: green).  For each formulation, there exist  a smaller-
sized (squared fil l  pattern) and a bigger-sized (striped fil l  pattern) counterpart .  
The experimental design to assess the BBB and glioma 
targeting ability of LNCs was as follows. On the one hand, 
as the cell internalization mechanisms may follow a size-
dependent pattern, the role played by particle size in the 
targeting properties has been assessed separately in 
undecorated and in CBD-adsorbed fluorescently-labeled 
LNCs. On the other hand, as the increase of particle size 
due to CBD adsorption within the 20-60 nm interval 
represents a higher percentage increase than in the most 
widely explored 100-nm range, should particle size play a 
statistically significant role in the targeting properties, the 
influence of CBD-decoration will be then evaluated for 
equally-sized LNCs to maintain the size variable constant. 
The BBB-targeting ability has been evaluated through 
uptake and permeability experiments conducted with the 
human brain endothelial cell line hCMEC/D3. The results 
obtained with the in vitro cell-based BBB model have also 
been validated with in vivo biodistribution data in healthy 
mice. 
The quantitative analysis of the in vitro BBB-targeting 
ability is shown in Figure 3. Results consistently 
demonstrated a significantly higher BBB-targeting effect 
for smaller LNCs (1.8-fold for undecorated LNCs, p < 
0.01 and 2.0-fold for CBD-adsorbed LNCs, p<0.01). 
Given the influence of particle size on the BBB targeting 
ability, the role played by CBD-adsorption was then 
assessed from a comparison of equally-sized LNCs. The 
adsorption of CBD on LNCs enhanced by 1.4-fold (p < 
0.05) the BBB targeting ability of their undecorated 
equally-sized counterparts. The 3D reconstructions from 
the Z-stacks of the images taken by confocal microscopy 
evidenced qualitatively a perinuclear location of the LNCs 
within the hCMEC/D3 cells (Figure 4). 
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Figure 3: Quantitative analysis by flow cytometry of influence of particle size reduction and functionalization 
with CBD on the in vitro  BBB (left)  and glioma (right) targeting abili ty of LNCs.  *: p<0.05, **: p<0.01, ***: 
p<0.001. 
 
Figure 4: 3D reconstructions with the IMARIS software of the Z-stacks of confocal images with hCMEC/D3 cells:  
undecorated (left)  and CBD-adsorbed (right) fluorescently-labeled LNCs. Scale bar = 10 µm. 
Importantly, we verified that the nanocapsules 
themselves did not alter the barrier properties of the 
hCMEC/D3 monolayer before conducting the BBB 
permeability experiments with LNCs. Effectively, there 
were no statistically significant differences between the 
permeability coefficients of TRITC-dextran across the 
hCMEC/D3 monolayer in the presence and the absence of 
LNCs (1.67 ± 0.44 x 10-7 cm/s versus 1.77 ± 0.33 x 10-7 
cm/s, p>0.05). These results demonstrated the integrity of 
the BBB model throughout the 24 hours period evaluated 
and consequently the suitability of this model for 
evaluating the BBB transport ability of the LNCs. 
The quantitative analysis of the in vitro BBB-
permeability coefficients is shown in Figure 5. We have 
used herein the permeability coefficient as a robust 
parameter that readily enables the comparison of transport 
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efficiency (which is not the case for the transport ratio 
expressed as percentage of passage across the endothelial 
monolayer). Results from the permeability experiments 
were consistent with those obtained with uptake studies. 
The BBB permeability coefficients were significantly 
higher for smaller LNCs (2.8-fold for undecorated LNCs, 
p < 0.01 and 2.5-fold for CBD-adsorbed LNCs, p< 0.001). 
As particle size determined the permeability coefficient, 
the influence of CBD adsorption was then assessed from a 
comparison of equally-sized LNCs. The adsorption of 
CBD on LNCs enhanced by 5.2-fold (p < 0.001) the 
permeability coefficient of their undecorated equally-sized 
counterparts. 
 
Figure 5: Quantitative analysis of influence of particle size reduction and functionalization with CBD on the 
permeabili ty coefficient of LNCs of LNCs across the hCMEC/D3 monolayer.  *:  p<0.05, **: p<0.01, ***: p<0.001.  
These results have been validated with biodistribution 
studies. Although pathophysiological models have often 
been used to evaluate the brain targeting efficiency, given 
that BBB disruption only occurs in the most damaged 
brain areas, we aimed at evidencing targeting properties at 
earlier stages of the brain diseases with biodistribution 
studies in healthy mice. 
As the size distribution features of DiD-labeled LNCs 
were analogous to their DiO-labeled counterparts (Figure 
2), the same comparisons as those drawn in vitro have 
been made in vivo. We have determined the percentage of 
the injected dose per gram of organ in brain (Figure 6), 
blood, lungs, kidneys, heart, spleen and liver (Figure S2). 
The in vivo results confirmed the results obtained with 
the in vitro BBB model: a decrease in particle size yielded 
a higher transcytosis rate to brain (1.6-fold for undecorated 
LNCs, p < 0.05 and 2.2-fold for CBD-adsorbed LNCs, p < 
0.01). Given the influence of particle size on the brain 
distribution, the influence of CBD adsorption was then 
assessed from a comparison of equally-sized LNCs. The 
functionalization of LNCs with CBD enhanced by 2.4-fold 
(p < 0.01) the in vivo brain targeting of their undecorated 
equally-sized counterparts. The increase in brain levels 
highly correlated with higher available plasma 
concentration and, in most cases, with lower recognition 
by the reticuloendothelial organs (Figure S2). 
Remarkably, the enhancement in brain targeting 
achieved with the adsorption of CBD on LNCs 
outperformed by 6-fold that of the gluthatione 
functionalization strategy assessed in a seminal study with 
healthy mice that laid the foundations for the G-
Technology® (the main brain active strategy that has 
already entered clinical trials for the treatment of brain 
diseases) (54). The brain targeting ability of CBD-
decorated LNCs is likely mediated by receptor-mediated 
transcytosis across the brain endothelium (55). Among the 
many receptors located at the CNS level to which CBD 
binds, dopamine receptor has been reported to specifically 
locate at the BBB and has recently started being tested as a 
potential receptor to mediate brain targeting of 
nanocarriers with exogenous ligands (56). 
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Figure 6: Quantitative analysis of the in vivo  biodistribution of DiD-labeled LNCs in the brain of healthy mice 
expressed as percentage of the injected dose per gram of brain.  The colours and fil l  patterns of the LNC 
formulations correspond to those of figure 2.  *: p<0.05, **: p<0.01, ***: p<0.001.  
Altogether, the consistency between the in vitro and in 
vivo results served to validate our in vitro BBB model with 
the human brain endothelial cell line hCMEC/D3 as a 
versatile screening method to evaluate the passage of 
nanocarriers across the BBB that meets the high-
throughput demands in the early stages of the drug 
discovery and lacks ethical constraints. 
Analogously, the glioma targeting ability has been 
evaluated through uptake experiments conducted with the 
human glioblastoma cell line U373MG. To this end, we 
have utilized the same LNCs than for the BBB-targeting 
ability (Figure 2). 
The quantitative analysis of the in vitro glioma-
targeting ability is also shown in Figure 3. A decrease in 
particle size consistently yielded a higher in vitro uptake 
by human glioblastoma cells (3.0-fold for undecorated 
LNCs, p<0.05 and 3.5-fold for CBD-adsorbed LNCs, 
p<0.001). Given the effect of particle size on the cell 
uptake, the influence of CBD adsorption was then assessed 
from a comparison of equally-sized LNCs. The 
functionalization of LNCs with CBD enhanced by 3.4-fold 
(p < 0.001) the in vitro glioma targeting properties of their 
equally-sized undecorated counterparts. The 3D 
reconstruction from the Z-stacks of the images taken by 
confocal microscopy further support qualitatively the 
internalization of LNCs within the U373MG cells (Figure 
7). 
The enhancement in glioma targeting achieved with the 
adsorption of CBD on LNCs equals that observed with 
other targeting moieties such as the aptamer AS1411 (57) 
or angiopep-2 (58) and outperformed that reported for 
transferrin (59), T7 peptide (60) or mannose (59). The 
exogenous and non-peptide nature of CBD makes it less 
prone to develop competitive phenomena with 
physiological ligands or cause immunogenicity. 
A comparison of the uptake studies with both cell lines 
reveals that the enhancements in the targeting effects 
achieved with the reduction in LNC size (p < 0.05 for 
undecorated LNCs and p< 0.001 for CBD-functionalized 
LNCs) and CBD adsorption (p < 0.001) were statistically 
more significant with the human glioblastoma cells (Figure 
3). 
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Figure 7: Example of 3D reconstruction from the Z-stacks of the images taken by confocal microscopy for DiO-
labeled LNCs within U373MG cells.  
3.3. Determination of the in vitro efficacy of CBD-loaded 
LNCs as extended-release carriers against U373MG cells 
Monodisperse LNCs with the Labrafac®-Kolliphor® 
HS15 tandem loaded with CBD at a concentration of 15 % 
CBD/ Labrafac® WL1349 (w/w) were prepared in two 
different sizes for in vitro efficacy experiments under the 
assumption that LNCs contribute to overcome classical 
formulation problems associated with cannabinoids (61) 
and to attain a prolonged-release platform for this drug. 
The liquid lipid core of triglyceride oils was chosen on the 
grounds of the solubility of CBD to achieve both high 
encapsulation efficiencies and drug loading (Table S1). 
Concerning particle size, the encapsulation of CBD 
followed the inverse pattern than its adsorption: the 
percentage increase in particle size in comparison to their 
blank counterparts was more evident for the bigger LNCs 
(Figure 8). These results positively correlated with the 
percentage of CBD loading, which ranged from 4.30% for 
the smaller LNCs to 7.66% for the bigger ones (Table S1). 
Moreover, in agreement with the hypothesized 
encapsulation, the zeta potential profiles were not changed 
in comparison to those obtained for blank LNCs (Figure 
S1): values close to neutrality with high profile width were 
obtained in all cases. 
 
Figure 8: Average volume diameter of the different LNCs used to assess the  in vitro  efficacy against glioma: 
blank LNCs (orange) and CBD-loaded LNCs (pistachio).  The smaller-sized formulation of each type has a squared 
fil l  pattern, whereas the bigger-sized has a striped fil l  pattern.  
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The results from cell viability experiments are shown 
in Figure 9. Noticeably, none of the formulations of blank 
LNCs utilized as controls showed significant cytotoxicity 
against the U373MG cell line within the evaluated 
concentration range according to ISO 10993-5 (Biological 
evaluation of medical devices, Part 5: Tests for in vitro 
cytotoxicity). Therefore, all changes in the percentage of 
cell viability following treatment with CBD-loaded LNCs 
can be attributed to the extent of CBD released from the 
LNCs at each time point. 
 
Figure 9: Cytotoxicity of blank LNCs and CBD-loaded LNCs in different sizes against the human glioblastoma 
U373MG cell  l ine.  (a) Cytotoxicity of 20 nm-sized blank LNCs after 48 (orange) and 96 hours (red).  (b) 
Cytotoxicity of 40 nm-sized blank LNCs after 48 (orange) and 96 hours (red).  (c) Cytotoxicity of 20 nm-sized 
CBD-loaded LNCs after 48 (pistachio) and 96 hours (dark green).  (d) Cytotoxicity of 40 nm-sized blank LNCs 
after 48 (pistachio) and 96 hours (dark green).  
Free CBD showed a clear antiproliferative effect 
against the glioblastoma cells (IC50 = 29.1 µM, Figure S3). 
The encapsulation of CBD considerably increased this IC50 
value, as free CBD is readily available, whereas 
encapsulated CBD must be first released from the oily core 
of LNCs to exert its cytotoxic effect on glioma cells. 
Similar trends have been described for other drug-loaded 
carriers (56, 62, 63). 
The size of LNCs played a key role in the extent of 
CBD release and subsequent cytotoxicity: the smaller-
sized CBD-loaded LNCs reduced by 3.0-fold the IC50 
value achieved with the bigger-sized CBD-loaded LNCs 
both after 48 (202.6 µM versus 615.4 µM) and 96 hours 
(129.1 µM versus 375.4 µM). Moreover, as deduced from 
the reduction in the IC50 values from 48 to 96 hours, LNCs 
continued to release CBD. Accordingly, CBD-loaded 
LNCs act as efficient extended-release carriers with great 
potential for glioma therapy. 
4.  CONCLUSIONS 
The results presented herein serve to envision LNCs, 
prepared by the PIT method and loaded with CBD in their 
oily core and functionalized with CBD on their surface, as 
promising dually-targeted candidates for intravenous 
treatment of glioma. We have introduced, on the one hand, 
a pioneering functionalization strategy for brain tumor 
targeting of LNCs with this non-immunogenic and non-
psychotropic cannabinoid (with better targeting properties 
than some other targeting strategies that have already 
reached the clinical trials stage) and, on the other hand, 
nanocapsules as extended-release carriers of CBD at high 
drug loading to overcome the formulation issues usually 
associated with cannabinoids that have heretofore 
constrained their therapeutic potential. Moreover, to 
contribute to the rational design of nanocapsules, we have 
demonstrated that both the BBB and glioma targeting 
ability and the drug release rate can be tailored by varying 
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the particle size of LNCs. This fine size-tailoring can be 
achieved by the PIT method thanks to the herein-described 
linear univariate mathematical model as a function of the 
oily phase/surfactant mass ratio to increase the chances of 
success in the development of nanomedicines for the 
treatment of glioma and other brain diseases. 
Consequently, they deserve subsequent in vivo evaluation 
in an animal model of disease. 
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Supporting information  
Figure S1: Zeta potential  profiles for blank LNCs (a: smaller-sized formulation and d: bigger-sized formulation),  
CBD-decorated LNCs (b: smaller-sized formulation and e: bigger-sized formulation) and CBD-encapsulated LNCs 
(c: smaller-sized formulation and f:  bigger-sized formulation).  
Table S1: CBD adsorption/encapsulation efficiencies (AE/EE) and drug content (DC) of the different LNCs 
discussed in the manuscript.  
LNC formulation AE/EE (%) DC (%) 
Smaller-sized CBD-adsorbed LNCs 96.99 ± 2.58 1.55 ± 0.07 
Bigger-sized CBD-adsorbed LNCs 95.97 ± 4.72 2.17 ± 0.06 
Smaller-sized CBD-encapsulated LNCs 96.75 ± 1.45 4.30 ± 0.07 
Bigger-sized CBD-encapsulated LNCs 96.43 ± 3.25 7.66 ± 0.30 
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Figure S2: Quantitative analysis of the in vivo  biodistribution of DiD-labeled LNCs in healthy mice expressed as 
percentage of the injected dose per gram of organ: (a) blood, (b) lungs, (c) kidneys, (d) heart ,  (e) spleen and (f)  
l iver.  The colours and fil l  patterns of the LNC formulations correspond to  those of figure 2.  *: p<0.05, **: 
p<0.01, ***: p<0.001.  
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Figure S3: Antiproliferative effect of free CBD against the human glioblastoma U373MG cell line. 
 
 
